B+
Bull case
25%
Probability
Target price
$16.83
Analysis reference price unavailable
Analysis 2026-09-16 · RankAlpha Sentiment Codex
INFU
InfuSystemBNYSE American / Health Care Equipment & Services
Last Price
Quote time unavailable
Current thesis
Record Q2 revenue, improving adjusted EBITDA margin, Oncology growth, and accelerating Wound Care suggest operating leverage could strengthen if segment momentum persists. [#PR-EARNINGS-2026-08-11]
Posture
Constructive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta +0.0.
What can break
Analyst coverage and target provenance are unclear; no post-Q2 estimate revisions or rating changes were available.
Momentum
91
Value
65
Sentiment
44
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $13.25 · Bull $16.83 · Bear $9.25Analysis 2026-09-16; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-23 • Vendor: Data Vendor v1
Scores
As of 2026-10-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-09-16 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-23
Investment thesis
As of 2026-10-23
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-23. Definitions
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $16.83
Why
Momentum91 · Δ7d +4.1
Value65 · Δ7d +0.0
Sentiment44 · Δ7d -5.8
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Value remains the lead driver in the composite, 7D delta +0.0.
Contradictions & invalidation
- • Analyst coverage and target provenance are unclear; no post-Q2 estimate revisions or rating changes were available.
- • Failure to sustain Oncology growth after quarterly revenue first exceeded $20 million would weaken the scale thesis.
- • Reported GAAP growth was only 2.6%, and the GE Healthcare contract restructuring reduced quarterly revenue by $1.6 million.
Catalyst clock
2026-09-30
Q2 operating improvement gains recognition
Lead driver: Value · See fundamentals
Momentum
91
8% active weight
Current posture
7d trendImproving
Δ7d
+4.1
Δ21d
+4.8
Value
65
47% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
-0.3
Sentiment
44
45% active weight
Current posture
7d trendSoftening
Δ7d
-5.8
Δ21d
-15.0
Why this grade
Composite grade B. Momentum 91.5 / Value 64.8 / Sentiment 44.3
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-09-16. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$13.25
Analysis reference price unavailable
Analysis 2026-09-16 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$9.25
Analysis reference price unavailable
Analysis 2026-09-16 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-23
Fundamentals (TTM)
As of 2026-10-23
Market Cap
$277.65M
Beta
1.68
Shares Out
19.92M
P/E (TTM)
33.7
P/S (TTM)
1.27
P/FCF (TTM)
12.51
Rev YoY
+2.6%
EPS YoY
+25.1%
Gross Margin
+56.1%
Op Margin
+9.3%
Net Debt
$21.25M
Current Ratio
2.50
As of 2026-10-23 • Updated nightlySource: Internal modelMethods & Data